Pegfilgrastim biosimilar (Biocon/Mylan)

培非格司亭生物类似药 (Biocon/Mylan)

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePegfilgrastim biosimilar (Biocon/Mylan)
Drug Alias NamePegfilgrastim biosimilar (Biocon/Mylan)培非格司亭生物仿制药 (Biocon/Mylan)PEG-G-CSF (Biocon/Mylan)Pegfilgrastim-jmdbFulphila +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Global Approved IndicationsFebrile NeutropeniaNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/06/04
Country/TerritoryBulgariaUnited StatesUkraine +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiosimilar Collaborations Ireland LtdMylan Gmbh
Inactive CompaniesMylan Inc
Active IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AA13
Related LinksN/A